ATS 2020 Advance Program

1:27 Could OSA Cause Neurodegeneration and Dementia? What Are the Underlying Mechanisms? C.L. Phillips, PhD, Camperdown, Australia 1:47 Is OSA a Risk Factor for Cognitive Decline and Alzheimer’s Disease? Clinical Evidence A.W. Varga, MD, PhD, New York, NY 2:07 Sleep and Sleep Apnea in Parkinson Disease M. Kaminska, MD, Montreal, Canada 2:27 Should We Treat Sleep Apnea in Dementia Patients? N.C. Netzer, MD, PhD, Bad Aibling, Germany 2:47 Where to From Here? R. Osorio, MD, New York, NY BASIC • CLINICAL SCIENTIFIC SYMPOSIUM D89 NOVEL THERAPEUTIC MANAGEMENT IN NON-TUBERCULOUS MYCOBACTERIA Assembly on Pulmonary Infections and Tuberculosis 1:00 p.m. - 3:00 p.m. Target Audience Pulmonary physicians, primary care physicians, medical residents and students, pulmonary fellows, nurses, and nurse practitioners. Objectives At the conclusion of this session, the participant will be able to: • increase awareness of NTM, and novel prognostic indicators including phentopying and endotyping; • improve understand of the microbiome in NTM, its scientific and clinical relevance, and clinical implications; • increase awareness of new and exciting treatment modalities for NTM, and what may be in the pipeline. This session will cover new and exciting topics involving the care of patients with non-tuberculous mycobacteria. There is a new ways to categorize patients (phenotypes and endotypes) which can have important prognostic and management implications. The microbiome of NTM, which gives us understanding at the molecular nature of the disease process, is also a hot topic with new research findings. New and exciting treatments in NTM have emerged, including dual beta lactam therapy for rapidly growing mycobacterium, that will be covered. Other therapies, including inhaled nitric oxide, and GM-CSF will be presented. Finally, one of the most exciting topics in NTM, phage therapy, will be presented. Chairing: A. Basavaraj, MD, ATSF, NewYork, NY T.R. Aksamit, MD, Rochester, MN R. Thomson, MBBS, PhD, Greenslopes, Australia 1:00 State of the Art NTM Treatment in 2020 K.L. Winthrop, MD, MPH, Portland, OR 1:15 Phenotyping in Bronchiectasis and NTM J.D. Chalmers, MD, PhD, Dundee, United Kingdom 1:35 Microbiome in Bronchiectasis and NTM L.N. Segal, MD, New York, NY 1:55 Phage Treatment for NTM P. Turner, PhD, New Haven, CT 2:15 Dual Beta Lactam Therapy for Rapidly Growing Mycobacteria S.H. Kasperbauer, MD, Denver, CO 2:35 Nitric Oxide and Other Emerging Therapies K.N. Olivier, MD, MPH, ATSF, Bethesda, MD 2:55 Questions and Answers CLINICAL SCIENTIFIC SYMPOSIUM D90 HORIZONS IN EXTRACORPOREAL SUPPORT: EVIDENCE, ENIGMAS, AND WHAT'S COMING NEXT 1:00 p.m. - 3:00 p.m. Target Audience All those involved in critically ill adults and children with respiratory and/or cardiac failure who might benefit from ATS 2020 • Philadelphia, PA 146 WEDNESDAY • MAY 20